Innovation Showcases
Traditional toxicity testing relying on animal models and 2D cell cultures faces ethical, cost, and predictive limitations. Organoids—3D microtissues—offer a transformative solution by combining human relevance with structural complexity, bridging the gap between simplistic cell models and animal studies.
ACROBiosystems has developed a ready-to-use iPSC-derived organoid platform, featuring standardized kits, functional organoids (heart, brain, liver, intestine), and supporting factors. Each model is optimized for organ-specific toxicity assessment.
Validation studies using clinically proven toxic compounds demonstrate that organoids accurately replicate human toxicity responses, supporting their reliability for predictive toxicology.
As standardization and applications advance, organoid-based testing is poised to become a gold standard, reshaping drug safety evaluation and regulatory science.